Literature DB >> 29112494

Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH.

Pilar Garrido1, Azucena Aldaz2, Miguel Ángel Calleja3, Enrique De Álava4, María Jesús Lamas5, Miguel Martín6, Xavier Matías-Guiu7, José Palacios8, Ruth Vera9.   

Abstract

Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. Precision medicine is transforming clinical and biomedical research, as well as health care itself from a conceptual, as well as a methodological viewpoint, providing extraordinary opportunities to improve public health and lower the costs of the healthcare system. However, the implementation of precision medicine poses ethical-legal, regulatory, organizational and knowledge-related challenges. Without a national strategy, precision medicine, which will be implemented one way or another, could take place without the appropriate planning that can guarantee technical quality, equal access of all citizens to the best practices, violating the rights of patients and professionals and jeopardizing the solvency of the healthcare system. With this paper from the Spanish Societies of Medical Oncology (SEOM), Pathology (SEAP), and Hospital Pharmacy (SEFH) we highlight the need to institute a consensual national strategy for the development of precision medicine in our country, review the national and international context, comment on the opportunities and challenges for implementing precision medicine, and outline the objectives of a national strategy on precision medicine in cancer. Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29112494     DOI: 10.7399/fh.10877

Source DB:  PubMed          Journal:  Farm Hosp        ISSN: 1130-6343


  2 in total

1.  Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8-9 February 2018.

Authors:  Luca Mazzarella
Journal:  Ecancermedicalscience       Date:  2018-03-05

2.  Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain.

Authors:  A Rodríguez-Lescure; F A de la Peña; E Aranda; A Calvo; E Felip; P Garrido; R Vera
Journal:  Clin Transl Oncol       Date:  2020-06-12       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.